These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34148292)

  • 1. Fragment-based in silico design of SARS-CoV-2 main protease inhibitors.
    Ahmad S; Usman Mirza M; Yean Kee L; Nazir M; Abdul Rahman N; Trant JF; Abdullah I
    Chem Biol Drug Des; 2021 Oct; 98(4):604-619. PubMed ID: 34148292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the antiviral therapeutic potentialities of marine polycyclic lamellarin pyrrole alkaloids as promising inhibitors for SARS-CoV-2 and Zika main proteases (Mpro).
    Pereira F; Bedda L; Tammam MA; Alabdullah AK; Arafa R; El-Demerdash A
    J Biomol Struct Dyn; 2024 May; 42(8):3983-4001. PubMed ID: 37232419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L.
    Costanzi E; Kuzikov M; Esposito F; Albani S; Demitri N; Giabbai B; Camasta M; Tramontano E; Rossetti G; Zaliani A; Storici P
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease.
    Deeks HM; Walters RK; Barnoud J; Glowacki DR; Mulholland AJ
    J Chem Inf Model; 2020 Dec; 60(12):5803-5814. PubMed ID: 33174415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
    Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
    Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019- nCoVM
    Serseg T; Benarous K; Yousfi M
    Curr Comput Aided Drug Des; 2021; 17(3):469-479. PubMed ID: 32321407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
    Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
    Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
    [No Abstract]   [Full Text] [Related]  

  • 12. Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro.
    Silva RC; Freitas HF; Campos JM; Kimani NM; Silva CHTP; Borges RS; Pita SSR; Santos CBR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations.
    Liang S; Liu X; Zhang S; Li M; Zhang Q; Chen J
    Phys Chem Chem Phys; 2022 Jan; 24(3):1743-1759. PubMed ID: 34985081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
    Noroozi Tiyoula F; Aryapour H
    PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2.
    Mousavi SS; Karami A; Haghighi TM; Tumilaar SG; Fatimawali ; Idroes R; Mahmud S; Celik I; Ağagündüz D; Tallei TE; Emran TB; Capasso R
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics.
    Said MA; Albohy A; Abdelrahman MA; Ibrahim HS
    Eur J Pharm Sci; 2021 May; 160():105744. PubMed ID: 33540040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease.
    Basu S; Veeraraghavan B; Ramaiah S; Anbarasu A
    Microb Pathog; 2020 Dec; 149():104546. PubMed ID: 33011363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.